Telegram Group & Telegram Channel
艾伯维重磅IL-23抑制剂「​利生奇珠单抗​」​在华获批上市

艾伯维宣布其IL-23抑制剂利生奇珠单抗(喜开悦)在中国获批,用于治疗中重度活动性克罗恩病成年患者。这是全球首个获批用于该病症的IL-23抑制剂,也是国内首个配备随身给药器的IL-23抑制剂。利生奇珠单抗通过阻断IL-23p19亚基来选择性阻断IL-23,该细胞因子参与炎症过程,与多种慢性免疫介导疾病相关。利生奇珠单抗已在全球获得7项适应症批准,2024年销售额达到117.18亿美元。其治疗克罗恩病的疗效在多项III期研究中得到验证,显著提高患者内镜应答和临床缓解比例。克罗恩病是一种慢性、全身性胃肠道炎症疾病,病情可能随时间恶化,给患者带来极大的生活负担。

媒体报道
艾伯维重磅IL-23抑制剂「利生奇珠单抗」正式获中国上市审批 智慧芽_新药情报库
治疗克罗恩病!艾伯维 IL-23 抑制剂「利生奇珠单抗」国内获批上市 医药魔方
刚刚!艾伯维重磅IL-23抑制剂「利生奇珠单抗」在中国获批上市 医药魔方
艾伯维重磅IL-23抑制剂「利生奇珠单抗」在华获批上市 医药魔方

#热门话题



tg-me.com/readhub_cn/247329
Create:
Last Update:

艾伯维重磅IL-23抑制剂「​利生奇珠单抗​」​在华获批上市

艾伯维宣布其IL-23抑制剂利生奇珠单抗(喜开悦)在中国获批,用于治疗中重度活动性克罗恩病成年患者。这是全球首个获批用于该病症的IL-23抑制剂,也是国内首个配备随身给药器的IL-23抑制剂。利生奇珠单抗通过阻断IL-23p19亚基来选择性阻断IL-23,该细胞因子参与炎症过程,与多种慢性免疫介导疾病相关。利生奇珠单抗已在全球获得7项适应症批准,2024年销售额达到117.18亿美元。其治疗克罗恩病的疗效在多项III期研究中得到验证,显著提高患者内镜应答和临床缓解比例。克罗恩病是一种慢性、全身性胃肠道炎症疾病,病情可能随时间恶化,给患者带来极大的生活负担。

媒体报道
艾伯维重磅IL-23抑制剂「利生奇珠单抗」正式获中国上市审批 智慧芽_新药情报库
治疗克罗恩病!艾伯维 IL-23 抑制剂「利生奇珠单抗」国内获批上市 医药魔方
刚刚!艾伯维重磅IL-23抑制剂「利生奇珠单抗」在中国获批上市 医药魔方
艾伯维重磅IL-23抑制剂「利生奇珠单抗」在华获批上市 医药魔方

#热门话题

BY Readhub


Warning: Undefined variable $i in /var/www/tg-me/post.php on line 283

Share with your friend now:
tg-me.com/readhub_cn/247329

View MORE
Open in Telegram


Readhub Telegram | DID YOU KNOW?

Date: |

For some time, Mr. Durov and a few dozen staffers had no fixed headquarters, but rather traveled the world, setting up shop in one city after another, he told the Journal in 2016. The company now has its operational base in Dubai, though it says it doesn’t keep servers there.Mr. Durov maintains a yearslong friendship from his VK days with actor and tech investor Jared Leto, with whom he shares an ascetic lifestyle that eschews meat and alcohol.

That strategy is the acquisition of a value-priced company by a growth company. Using the growth company's higher-priced stock for the acquisition can produce outsized revenue and earnings growth. Even better is the use of cash, particularly in a growth period when financial aggressiveness is accepted and even positively viewed.he key public rationale behind this strategy is synergy - the 1+1=3 view. In many cases, synergy does occur and is valuable. However, in other cases, particularly as the strategy gains popularity, it doesn't. Joining two different organizations, workforces and cultures is a challenge. Simply putting two separate organizations together necessarily creates disruptions and conflicts that can undermine both operations.

Readhub from us


Telegram Readhub
FROM USA